Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S050 - Skinternal Medicine: An Update on Cutaneous Manifestations of Systemic Disease

Monday, February 19; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize cutaneous manifestations of systemic disease
  • Develop a scheme for evaluation of patients with cutaneous diseases that might reflect internal diseases
  • Formulate a plan for management of patients with systemic therapies

Description

The skin is frequently reflective of internal disease. This session will update the attendees with new aspects of such diseases and prepare them for developing effective, efficient plans for evaluation of such patients. In addition, attendees will be provided with a therapeutic scheme for cost-effective management. Off-label uses of medications will occur, but we will use the best level of evidence available for the basis of the therapeutic discussions. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.

Disclosures

  • Bolognia, Jean L., MD: Elsevier Inc. – O(IP);
  • Callen, Jeffrey Phillip, MD: 3M Pharmaceuticals – SH(ST); Abbott Laboratories – SH(ST); AbbVie – SH(ST); Allergan, Inc – SH(ST); Amgen – C(H); Biogen – Speaker/Faculty Education(H); Celgene – SH(ST); Eli Lilly and Company – C(H); JAMA – B(H); Johnson and Johnson – SH(ST); Pfizer Inc. – SH(ST); Procter & Gamble Company – SH(ST); UpToDate, Inc. – B(H);
  • Fett, Nicole, MD: La Roche-Posay Laboratorie Pharmaceutique – I(S); Pfizer Inc. – I(S);
  • Harp, Joanna L., MD: no financial relationships exist with commercial interests.
  • Jorizzo, Joseph L., MD: Amgen – A(H); LEO Pharma, US – A(H);
  • Maderal, Andrea, MD: no financial relationships exist with commercial interests.
  • Rosenbach, Misha, MD: Derm101 – Independent Contractor(H); Endocyte – I(NC); Gilead Sciences, Inc – I(Grants/Research Funding); GlaxoSmithKline – C(NC); Merck & Co., Inc – A(H); Promet Therapeutics, LLC – C(H);
  • Schadt, Courtney Reynolds, MD: no financial relationships exist with commercial interests.
  • Shinkai, Kanade, MD, PhD: no financial relationships exist with commercial interests.
  • Stratman, Erik Joseph, MD: no financial relationships exist with commercial interests.
  • Strowd, Lindsay Chaney, MD: Actelion – SP(H);
Schedule
Monday, February 19
9:00 AM
Dr. Callen / Introduction
9:05 AM
Dr. Stratman / Case 1
9:20 AM
Dr. Jorizzo / Case 2
9:35 AM
Dr. Schadt / Case 3
9:50 AM
Dr. Fett / Case 4
10:05 AM
Dr. Harp / Case 5
10:20 AM
Dr. Rosenbach / Case 6
10:35 AM
Dr. Strowd / Case 7
10:50 AM
Dr. Shinkai / Case 8
11:05 AM
Dr. Bolognia / Case 9
11:20 AM
Dr. Maderal / Case 10
11:35 AM
Dr. Callen / Case 11
11:50 AM
All faculty / Q&A
Event Details
  • Date
    Monday, February 19
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 28D
  • CME Credits
    3.00
  • Type
    MOC
Directors/Co-Directors
  • Jeffrey Phillip Callen, MD, FAAD
Speakers
  • Andrea Maderal, MD, FAAD
  • Courtney Reynolds Schadt, MD, FAAD
  • Erik Joseph Stratman, MD, FAAD
  • Jean L. Bolognia, MD, FAAD
  • Joanna L. Harp, MD, FAAD
  • Joseph L. Jorizzo, MD, FAAD - Handout
  • Kanade Shinkai, MD, PhD, FAAD
  • Lindsay Chaney Strowd, MD, FAAD
  • Misha Rosenbach, MD, FAAD
  • Nicole Fett, MD, FAAD